MRTX0902 CAS No.:2654743-22-1

Introduction:

MRTX0902 CAS No.:2654743-22-1 is a novel and potent small molecule inhibitor of KRASG12C. KRASG12C is a type of cancer gene that is responsible for the growth of several different types of cancer. MRTX0902 has demonstrated excellent pre-clinical and clinical results, showing a significant reduction in tumor growth in various cancer models. The compound has already completed Phase 1 clinical trials with promising results.

MRTX0902 is set to revolutionize the treatment of various types of cancer, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. Its unique mechanism of action and high potency make it a potential blockbuster drug in the pharmaceutical industry.

Features and Benefits:

1. Potent KRASG12C inhibitor:

MRTX0902 is a potent KRASG12C inhibitor that binds to the mutant KRAS oncoprotein, inhibiting its activity and preventing cancer cell proliferation. This mechanism of action is crucial as KRAS mutations are found in almost 30% of all human cancers.

2. Promising pre-clinical and clinical data:

MRTX0902 has demonstrated excellent pre-clinical and clinical results, showing a significant reduction in tumor growth in various cancer models. The compound has already completed Phase 1 clinical trials with promising results. The results indicated that the drug is well-tolerated with no dose-limiting toxicities observed.

3. Potential blockbuster drug in the pharmaceutical industry:

MRTX0902 has the potential to become a blockbuster drug in the pharmaceutical industry due to its unique mechanism of action and high potency. The drug has already garnered significant interest from major pharmaceutical companies, and it is expected to attract more attention from investors and stakeholders as it moves closer to approval.

4. Wide application:

MRTX0902 shows significant promise in treating various types of cancer, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. It has shown promising results as both a monotherapy and in combination with other drugs.

5. Favorable safety and efficacy profile:

MRTX0902 has demonstrated a favorable safety and efficacy profile, with no dose-limiting toxicities observed in clinical trials. This makes it an attractive option for cancer patients who require long-term treatment.

Conclusion:

MRTX0902 is a potent and promising small molecule inhibitor of KRASG12C. It has demonstrated excellent pre-clinical and clinical results and has the potential to become a blockbuster drug in the pharmaceutical industry. Its unique mechanism of action and high potency make it an attractive option for treating various types of cancer. As a manufacturer, we strive to provide high-quality products and top-notch service to our clients. We believe that MRTX0902 will be a game-changer in the field of oncology, and we are proud to offer this innovative product to our customers.

Chemical Structure : MRTX 0902

CAS No.: 2654743-22-1

 

MRTX 0902(MRTX0902)

Catalog No.: URK-V2328 Only Used For Lab.

MRTX0902 is a highly potent, selective SOS1 inhibitor with binding IC50 of 2 nM, cellular IC50 of 33 nM (pERK).

Biological Activity

MRTX0902 is a highly potent, selective SOS1 inhibitor with binding IC50 of 2 nM, cellular IC50 of 33 nM (pERK).
MRTX0902 displays weak to no affinity for SOS2 with IC50 of >10 uM.
MRTX0902 exhibits promising potency, selectivity, and exposure in preclinical species.
MRTX0902 in combined with MRTX849 demonstrates durable regression in KRasG12C NSCLC and CRC PDX models.
MRTX0902 demonstrates improved efficacy with osimertinib (EGFRi), VS-6766 (RAF/MEKc) in MAPK tumor models.

Physicochemical Properties

References

URK-V2328_COA

URK-V2328_SDS

URK-V2328_TDS

 

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, and we do not provide products and services for any personal use!

Why choose us?

• We take great pride in our ability to deliver top-quality Ras-Raf-MAPK-ERK Pathway Library products and services at an affordable price.
• We operate various businesses with self-confidence and unity business philosophy, and are determined to provide customers with the highest quality MRTX0902 CAS No.:2654743-22-1 and services.
• Our company is committed to providing top-notch customer service and high-quality Ras-Raf-MAPK-ERK Pathway Library products to customers around the world.
• Our company has accumulated rich experience in the industry of MRTX0902 CAS No.:2654743-22-1, has strong innovation ability, and has a strong technical research and development team. We continue to pursue product quality and innovation, and based on integrity, we have come to where we are today. We will continue to improve in the future!
• Our company has built its success on providing reliable and innovative Ras-Raf-MAPK-ERK Pathway Library products to customers around the world.
• We have been adhering to the business philosophy of 'Quality, Sincerity, and Innovation' to continuously enhance market competitiveness, serve business colleagues loyally.
• Our company has a strong reputation for delivering high-quality and reliable Ras-Raf-MAPK-ERK Pathway Library products and services to customers worldwide.
• We strive to create a warm corporate atmosphere and a happy working environment, with more humanistic care.
• We are a Chinese factory with a range of high-quality Ras-Raf-MAPK-ERK Pathway Library products and professional services.
• We actively promote the maximization of enterprise value, take social and economic responsibility, and realize the harmonious win-win situation for all stakeholders.

Hot Tags: mrtx0902 cas no.:2654743-22-1, China mrtx0902 cas no.:2654743-22-1, agonists for chemokine activation, epigenetic library for epigenetic analysis of epigenetic editing, epigenetic library for epigenetic analysis of histone modification, inhibitors for enzyme activity, epigenetic library for epigenetic analysis of epigenetic biomarker validation, agonists for polyclonal antibody activation